Latest Stocks: HC Wainwright Reiterates “Buy” Rating for Nabriva Therapeutics AG – (NBRV)

Latest Stocks: HC Wainwright Reiterates “Buy” Rating for Nabriva Therapeutics AG – (NBRV)

Nabriva Therapeutics AG – (NASDAQ:NBRV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued on Friday, May 12th.

Several other brokerages have also recently issued reports on NBRV. Needham & Company LLC reissued a “buy” rating and set a $15.00 price target on shares of Nabriva Therapeutics AG – in a research report on Monday, March 27th. Cantor Fitzgerald reissued a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG – in a research report on Tuesday, April 11th. Zacks Investment Research cut shares of Nabriva Therapeutics AG – from a “hold” rating to a “sell” rating in a report on Thursday, January 26th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG – in a report on Tuesday, January 31st. Seven investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $15.29.

Shares of Nabriva Therapeutics AG – (NBRV) opened at 9.73 on Friday. The stock has a 50 day moving average of $10.29 and a 200 day moving average of $8.89. The company’s market cap is $264.75 million. Nabriva Therapeutics AG – has a 12-month low of $3.52 and a 12-month high of $12.75.

In related news, major shareholder Hbm Healthcare Investments (Ca sold 90,594 shares of the firm’s stock in a transaction that occurred on Monday, April 10th. The shares were sold at an average price of $10.96, for a total value of $992,910.24. Following the sale, the insider now owns 269,371 shares of the company’s stock, valued at $2,952,306.16. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director George Harrison Talbot sold 325 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the completion of the sale, the director now directly owns 3,854 shares in the company, valued at approximately $387,558.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 166,703 shares of company stock worth $1,911,919.

Hedge funds have recently added to or reduced their stakes in the company. Novo A S boosted its stake in Nabriva Therapeutics AG – by 108.3% in the fourth quarter. Novo A S now owns 2,326,544 shares of the biotechnology company’s stock worth $13,866,000 after buying an additional 1,209,884 shares during the last quarter. Vivo Capital LLC boosted its stake in Nabriva Therapeutics AG – by 27.6% in the fourth quarter. Vivo Capital LLC now owns 4,021,559 shares of the biotechnology company’s stock worth $23,968,000 after buying an additional 869,859 shares during the last quarter. Orbimed Advisors LLC boosted its stake in Nabriva Therapeutics AG – by 27.6% in the fourth quarter. Orbimed Advisors LLC now owns 1,677,940 shares of the biotechnology company’s stock worth $10,001,000 after buying an additional 362,940 shares during the last quarter. Baker BROS. Advisors LP bought a new stake in Nabriva Therapeutics AG – during the third quarter worth $2,468,000. Finally, Wellington Management Group LLP boosted its stake in Nabriva Therapeutics AG – by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. 42.86% of the stock is currently owned by institutional investors. About Nabriva Therapeutics AG –

Related posts

Leave a Comment